Therapeutic efficacy of suppressing the JAK/STAT pathway in models of neuroinflammation (P5199) As such, targeting JAKs has implications for treating autoimmune inflammation of the brain. We used a JAK1/2 inhibitor, AZD1480, to test the potential of inhibiting the JAK/STAT pathway in EAE. AZD...
Therapeutic Potential of Targeting the JAK/STAT Pathway in Psoriasis: Focus on TYK2 Inhibitiondoi:10.3390/jcm13113091PSORIASISSKIN diseasesTHROMBOEMBOLISMCATALYTIC domainsCHRONIC diseasesADALIMUMABPsoriasis is an inflammatory skin disease with a chronic relapsing course and an often-detrimental impac...
Targeting the Interleukin-6/Jak/Stat Pathway in Human Malignancies The Janus kinase/signal transducer and activator of transcription (Jak/Stat) pathway was discovered 20 years ago as a mediator of cytokine signaling. Since... P Sansone,J Bromberg - 《Journal of Clinical Oncology Official Journal ...
cGAS-STING signaling has more recently been recognized as a key pathway in the initiation and pathogenesis of inflammatory diseases, including cancer, autoimmune and neurodegenerative diseases [5]. The central nervous system (CNS) is a highly regulated and intricate environment and requires tight contro...
JAK inhibitor selectivity: new opportunities, better drugs? Article 09 September 2024 Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach Article 05 January 2022 Kinase inhibition in autoimmunity and inflammation Article 19 October 2020 Change...
MSCs also release cytokines like IL-6, activating the JAK/STAT pathway for self-potentiation into chondrocytes [27]. This is crucial in degenerative cartilage conditions like osteoarthritis, where resident chondrocytes experience significant loss or apoptosis [28]. However, the regenerative properties ...
K. et al. Therapeutic targeting of the G-CSF receptor reduces neutrophil trafficking and joint inflammation in antibody-mediated inflammatory arthritis. J. Immunol. 197, 4392–4402 (2016). Article CAS PubMed Google Scholar Lee, M. C. et al. G-CSF receptor blockade ameliorates arthritic pain...
Osimertinib is a novel oral, irreversible third-generation EGFR-TKI that targets EGFR-sensitizing and T790M resistance mutations [14,15]. Osimertinib irreversibly and specifically binds to the EGFR tyrosine kinase domain in a covalent bond formation manner by targeting the cysteine at position 797 in...
Moreover, PML targeting hampers breast cancer initiation and metastatic seeding. Mechanistically, this biological activity relies on the regulation of the stem cell gene SOX9 through interaction of PML with its promoter region. Altogether, we identify a novel pathway sustaining breast cancer ...
Chronic liver injury with any etiology can progress to fibrosis and the end-stage diseases cirrhosis and hepatocellular carcinoma. The progression of liver disease is controlled by a variety of factors, including liver injury, inflammatory cells, inflamm